Agarwal Arjun 4

What Happened Arjun Agarwal, Senior Vice President, Finance at Oruka Therapeutics (ORKA), sold a total of 1,587 shares in two open-market transactions on June 22, 2026. He sold 888 shares at $80.01 each for $71,049, and 699 shares at $82.14 each for $57,419, for aggregate proceeds of $128,468. These were sales (not purchases) and thus represent dispositions of stock rather than a bullish buy signal.

Key Details

• Transaction dates and prices: 2026-06-22 — 888 shares @ $80.01; 2026-06-22 — 699 shares @ $82.14.
• Total shares sold: 1,587; Total proceeds: $128,468.
• Shares owned after transaction: Not specified in the Form 4 filing.
• Footnote: Sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026 (pre-arranged trading plan).
• Timeliness: Reported on 2026-06-22 for transactions dated 2026-06-22 (filed same day).

Context Sales made under a Rule 10b5-1 plan are pre-scheduled and are commonly used by insiders to execute routine sales while reducing concerns about trading on material nonpublic information. As these were outright sales (transaction code S), they decrease the insider's holdings but do not, by themselves, indicate why the shares were sold.